Synthesis of C-15 Vindoline Analogues by
Palladium-Catalyzed Cross-Coupling Reactions
Peter D. Johnson, Jeong-Hun Sohn, and Viresh H. Rawal*
Department of Chemistry, UniVersity of Chicago,
5735 South Ellis AVenue, Chicago, Illinois 60637
ReceiVed June 16, 2006
Described are general protocols for the rapid construction of
various C-15-substituted analogues of vindoline using palladi-
um-catalyzed cross-coupling reactions. The required bromo-
and iodovindolines were prepared in high yield by the reac-
tion of vindoline with N-bromosuccinimide or N-iodosuccini-
mide, respectively. The study not only led to the preparation
of a number of structurally novel vindoline analogues but
also opens the door to new strategies for the synthesis of
vinblastine, vincristine, and related anticancer agents. Also
described is the conversion of ent-tabersonine to ent-
vindoline.
FIGURE 1. Clinically efficacious bisindole alkaloids and derivatives.
more naturally abundant vindoline and catharanthine by connec-
tion between C-15 at the former and C-18′ at the latter.6 The
coupling of these compounds has been accomplished several
times and inevitably takes advantage of the nucleophilicity of
vindoline at C-15.7 Recent efforts by Fahy have also made use
of this reactivity to elaborate the vindoline skeleton by addition
to glycolates.8 Our interest in the total synthesis of vinblastine
drew our attention to the possibility of installing a halogen at
C-15 of vindoline, which would allow for further elaboration at
this position by utilizing the broad spectrum of cross-coupling
reactions.9 These reactions are typically performed under mild
conditionsandprovideahighdegreeoffunctionalgrouptolerance.
The implementation of this chemistry would allow introduction
of novel substituents at C-15, in addition to providing a versatile
scaffold from which further synthetic elaborations could provide
a new synthesis of vinblastine, vincristine, and related compounds.
Initial concerns about the electron-rich nature of the aryl ring,
which slows down oxidative addition of Pd, prompted us to first
investigate the feasibility of cross-coupling of such systems using
a model compound. Thus a substituted carbazole containing the
essential features of 15-bromovindoline was first synthesized to
Vinblastine (1) and vincristine (2) are two bisindole alkaloid
natural products isolated from the Madagascar periwinkle, Catha-
ranthus roseus G. Don (Figure 1).1 Both possess considerable
antimitotic activity and thus have found use in treatment for
various carcinomas, particularly childhood leukemia and Hodg-
kin’s disease.2 The low natural availability and cytotoxic proper-
ties of these molecules have meant that considerable synthetic
efforts have been expended to find efficacious analogues. In the
40 years since the isolation of vinblastine, two such compounds,
vindesine (3, Eldesine, Lilly)3 and vinorelbine (4, Navelbine,
Pierre-Fabre),4 have found use in clinical treatment. A third,
vinflunine (5, Javlor, Pierre-Fabre/Bristol-Myers-Squibb), is cur-
rently in phase III clinical trials.5 The suggestion that these latter
two compounds have similar, but different, modes of action to
the natural compounds is encouraging for the prospect of further
analogues to tackle cross-resistance.
(6) (a) For a review on synthetic studies, see: Antitumor Bisindole
Alkaloids from Catharanthus roseus (L.). The Alkaloids; Brossi, A.,
Suffness, M., Eds.; Academic Press, Inc.; San Diego, 1990; Vol. 37, Chapter
2, pp 77-131. (b) Mangeney, P.; Andriamialisoa, R. Z.; Langlois, N.;
Langlois, Y.; Potier, P. J. Am. Chem. Soc. 1979, 101, 2243. (c) Kutney, J.
P.; Choi, L. S. L.; Nakano, J.; Tsukamoto, H.; McHugh, M.; Boulet, C. A.
Heterocycles 1988, 27, 1845. (d) Kuehne, M. E.; Matson, P. A.; Bornmann,
W. G. J. Org. Chem. 1991, 56, 513. (e) Magnus, P.; Mendoza, J. S.;
Stamford, A.; Ladlow, M.; Willis, P. J. Am. Chem. Soc. 1992, 114, 10232.
(f) Yokoshima, S.; Ueda, T.; Kobayashi, S.; Ayato, S.; Kuboyama, T.;
Tokuyama, H.; Fukuyama, T. J. Am. Chem. Soc. 2002, 124, 2137.
(7) (a) Harley-Mason, J.; Atta-Ur-Rahman. Tetrahedron 1980, 36, 1057.
(b) Kutney, J. P.; Beck, J.; Bylsma, F.; Cretney, W. J. J. Am. Chem. Soc.
1968, 90, 4504. (c) Magnus, P.; Mendoza, J. S.; Stamford, A., Ladlow,
M.; Willis, P. J. Am. Chem. Soc. 1992, 114, 10232. (d) Langlois, N.;
Gueritte, F.; Langlois, Y., Potier, P. J. Am. Chem. Soc. 1976, 98, 7017. (e)
Vukovic, J.; Goodbody, A. E.; Kutney, J. P.; Misawa, M. Tetrahedron 1988,
44, 325. (f) Misawa, M.; Endo, T.; Goodbody, A.; Vukovic, J.; Chapple,
C.; Choi, L.; Kutney, J. P. Phytochemistry 1988, 27, 1355. Tabakovic, T.;
Gunic, E.; Juranic, I. J. Org. Chem. 1997, 62, 947.
In addition, there have been a number of efforts to synthesize
vinblastine, both de novo and semisynthetically, from the much
(1) (a) Noble, R. L.; Beer, C. T.; Cutts, J. H. Ann. N.Y. Acad. Sci. 1958,
76, 882. (b) Svoboda, G. H.; Neuss, N.; Gorman, M. J. Am. Pharm. Assoc.
Sci. Ed. 1959, 48, 659.
(2) For a review of the medicinal chemistry of vinblastine, see: Antitumor
Bisindole Alkaloids from Catharanthus roseus (L.). The Alkaloids; Brossi,
A., Suffness, M., Eds.; Academic Press, Inc.; San Diego, 1990; Vol. 37,
Chapters 3 and 4, pp 133-204.
(3) (a) Barnett, C. J.; Cullinan, G. J.; Gerzon, K.; Hoying, R. C.; Jones,
W. E.; Newlon, W. M.; Poore, G. A.; Robison, R. L.; Sweeney, M. J.;
Todd, G. C.; Dyke, R. W.; Nelson, R. L. J. Med. Chem. 1978, 21, 88. (b)
Gokbuget, N.; Hoelzer, D. Leuk. Lymphoma 1997, 26, 497.
(4) (a) Potier, P. Semin. Oncol. 1989, 16, 2. (b) Gregory, R. K.; Smith,
I. E. Br. J. Cancer 2000, 82, 1907.
(5) (a) Fahy, J.; Duflos, A.; Ribet, J. P.; Jacquesy, J. C.; Berrier, C.;
Jouannetaud, M. P.; Zunino, F. J. Am. Chem. Soc. 1997, 119, 8576. (b)
Hill, B. T. Curr. Pharm. Des. 2001, 7, 1199.
(8) Fahy, J.; du Boullay, V. T.; Bigg, D. C. H. Bioorg. Med. Chem. Lett.
2002, 12, 505.
(9) During the preparation of this manuscript, a communication describing
some similar transformations was published: Fekete, M.; Kalonits, P.; Novak,
L. Heterocycles 2005, 65, 165. This communication reports the slow nature
of the Suzuki coupling of 15-bromovindoline, in contrast to our findings.
10.1021/jo061243y CCC: $33.50 © 2006 American Chemical Society
Published on Web 09/07/2006
J. Org. Chem. 2006, 71, 7899-7902
7899